Korro Bio, Inc. - 8-K Filing
Korro Bio dosed first cohort in Phase 1/2 trial for KRRO-121, an RNA-editing therapy targeting hyperammonemia. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $KRRO
More Regulatory news
- CENTRUS ENERGY CORP - 8-K Filing
- SAGA COMMUNICATIONS INC - 8-K Filing
- NextBoat Inc. - 8-K Filing
- CIVISTA BANCSHARES, INC. - 8-K Filing
- RF Acquisition Corp II - 10-Q Filing
- ORASURE TECHNOLOGIES INC - 10-Q Filing
- Rocket Companies, Inc. - 8-K Filing
- Applied Aerospace & Defense, Inc. - 10-Q Filing
- Palomar Holdings, Inc. - 8-K Filing
- UNITED GUARDIAN INC - 10-Q Filing